Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.69 |
| ▸ | XPO1 | O14980 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | ATF1 | P18846 | 3/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6288528 | 0.89 | ATF1 (0.68) | CNR2XPO1LMNAGLAATF1 | |
| SCHEMBL5083338 | 0.84 | CNR2 (0.85) | CNR2 | |
| SCHEMBL5779473 | 0.82 | CNR2 (1.00) | CNR2 | |
| SCHEMBL5780688 | 0.82 | CNR2 (1.00) | CNR2 | |
| SCHEMBL5780667 | 0.82 | CNR2 (0.81) | CNR2 | |
| SCHEMBL4745657 | 0.82 | CNR2 (0.76) | CNR2LMNAGLA | |
| SCHEMBL2307377 | 0.80 | NFKB1 (0.61) | XPO1LMNAATF1NFKB1 | |
| SCHEMBL3380605 | 0.80 | CNR2 (1.00) | CNR2 | |
| SCHEMBL5780820 | 0.80 | CNR2 (0.87) | CNR2 | |
| SCHEMBL5083119 | 0.80 | CNR2 (0.80) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008112156-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112156-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | CNR2 496/4885XPO1 546/4885LMNA 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.